261 related articles for article (PubMed ID: 36123506)
1. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.
Zhao L; Wang Y; Tian T; Rao X; Dong W; Zhang J; Yang Y; Tao Q; Peng F; Shen C; Wang S; Liu H; Zeng X; Zhou W
Hepatol Int; 2022 Dec; 16(6):1339-1352. PubMed ID: 36123506
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
5. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis.
Schäffer AA; Dominguez DA; Chapman LM; Gertz EM; Budhu A; Forgues M; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Wu X; Bayarsaikhan E; Harris CC; Ruchirawat M; Ruppin E; Wang XW
BMC Genomics; 2021 Nov; 22(1):814. PubMed ID: 34763675
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes.
Song Z; Lin S; Wu X; Ren X; Wu Y; Wen H; Qian B; Lin H; Huang Y; Zhao C; Wang N; Huang Y; Peng B; Li X; Peng H; Shen S
Hepatol Int; 2023 Oct; 17(5):1300-1317. PubMed ID: 37368186
[TBL] [Abstract][Full Text] [Related]
7. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
Xue TC; Zhang BH; Ye SL; Ren ZG
Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
[TBL] [Abstract][Full Text] [Related]
10. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.
Chen J; He J; Deng M; Wu HY; Shi J; Mao L; Sun Q; Tang M; Fan XS; Qiu YD; Huang Q
Hum Pathol; 2017 Jun; 64():118-127. PubMed ID: 28431889
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.
Zhou YW; Li QF; Chen YY; Wang K; Pu D; Chen XR; Li CH; Jiang L; Wang Y; Li Q; Yang Y; Gou HF; Bi F; Liu JY; Chen Y; Qiu M
Eur J Surg Oncol; 2022 Jul; 48(7):1559-1566. PubMed ID: 35115213
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers.
Lee CH; Hsieh SY; Chang CJ; Lin YJ
J Gastroenterol Hepatol; 2013 Jan; 28(1):122-7. PubMed ID: 23034166
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study.
Yang Z; Shi G
Cancer Med; 2022 Feb; 11(3):692-704. PubMed ID: 34862762
[TBL] [Abstract][Full Text] [Related]
18. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
[TBL] [Abstract][Full Text] [Related]
19. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
